<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758771</url>
  </required_header>
  <id_info>
    <org_study_id>10-02116</org_study_id>
    <nct_id>NCT00758771</nct_id>
  </id_info>
  <brief_title>Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents</brief_title>
  <acronym>GIST</acronym>
  <official_title>Using State-of-the-art Rheological Methods to Characterize CF Sputum and the Effects of Mucoactive Agents: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the rheological properties of cystic fibrosis
      (CF) and healthy sputum and to examine the effects of mucoactive agents on the rheology of CF
      and healthy sputum. By collaborating with Genentech, the investigators (scientists at UCSF)
      plan to incorporate the latest scientific findings into our work to discover and develop new
      treatments for CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two major mechanisms for mucus clearance in the airway, both of which are dependent
      upon optimal mucus viscosity and elasticity. These mechanisms are severely impaired in cystic
      fibrosis. The physical properties of sputum can be measured using rheological methods,
      enabling comparison between mucus in health and in disease. Therapies which enhance mucus
      clearance from the airway and decrease the volume of airway secretions are collectively
      called &quot;mucoactive agents.&quot; Therapies which specifically disrupt innate mucus architecture by
      breaking intermolecular entanglements and bonds are called mucolytic agents. Mucolytic drugs
      can be considered in three general categories: classic mucolytics (n-acetylcysteine), peptide
      mucolytics (PulmozymeÂ®), and non-destructive mucolytics (hypertonic saline). Using
      state-of-the-art rheological methods, we can characterize the physical properties of CF mucus
      and measure the rheologic effects of mucoactive drugs more accurately and reproducibly than
      what has been previously done in the literature. In this way, we will determine which of the
      current mucoactive agents are most effective in normalizing sputum rheology in CF, and we
      will gain important insights about the limitations of current mucoactive drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Shear Rheology</measure>
    <time_frame>Cross-sectional</time_frame>
    <description>Baseline measure of sputum shear rheology</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis</arm_group_label>
    <description>People who have been diagnosed with cystic fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>People who do not have cystic fibrosis and who do not have any other lung conditions</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People who have cystic fibrosis and those who do not have any lung disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy control subjects:

               -  Age 18-65

               -  No history of lung disease or cardiac disease

          -  Cystic fibrosis subjects:

               -  Age 18-65

               -  Diagnosis of CF - sweat chloride values &gt; 60 mM on pilocarpine iontophoresis
                  sweat tests and/or 2 allelic CF-producing mutations by genetic analysis

        Exclusion Criteria:

          -  Use of recreational drugs within 1 year prior to enrollment

          -  Use of tobacco within 1 year prior to enrollment, or &gt; 10 pack-year tobacco history

          -  Upper respiratory tract infection in the 4 weeks prior to enrollment in the study

          -  Current use of antihistamines to treat allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF Airway Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://airway.ucsf.edu</url>
    <description>UCSF Airway Clinical Research Center website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>January 22, 2014</results_first_submitted>
  <results_first_submitted_qc>January 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2014</results_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cystic Fibrosis</title>
          <description>Individuals who have been diagnosed with cystic fibrosis.</description>
        </group>
        <group group_id="P2">
          <title>Healthy</title>
          <description>Individuals who do not have cystic fibrosis and who do not have any other lung conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cystic Fibrosis</title>
          <description>Individuals who have been diagnosed with cystic fibrosis.</description>
        </group>
        <group group_id="B2">
          <title>Healthy</title>
          <description>Individuals who do not have cystic fibrosis and who do not have any other lung conditions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="12.8"/>
                    <measurement group_id="B2" value="41.9" spread="10.8"/>
                    <measurement group_id="B3" value="38.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Shear Rheology</title>
        <description>Baseline measure of sputum shear rheology</description>
        <time_frame>Cross-sectional</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cystic Fibrosis</title>
            <description>Individuals who have been diagnosed with cystic fibrosis.</description>
          </group>
          <group group_id="O2">
            <title>Healthy</title>
            <description>Individuals who do not have cystic fibrosis and who do not have any other lung conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Shear Rheology</title>
          <description>Baseline measure of sputum shear rheology</description>
          <units>Pascal</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.0"/>
                    <measurement group_id="O2" value="1.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cystic Fibrosis</title>
          <description>Individuals who have been diagnosed with cystic fibrosis.</description>
        </group>
        <group group_id="E2">
          <title>Healthy</title>
          <description>Individuals who do not have cystic fibrosis and who do not have any other lung conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John V. Fahy, MD, MSc</name_or_title>
      <organization>UCSF</organization>
      <phone>4154769940</phone>
      <email>john.fahy@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

